JNJ

225.07

-1.1%↓

ABT

92.85

+1.8%↑

MDT

82.92

-0.55%↓

115.57

+0.14%↑

VEEV

160.16

-0.42%↓

JNJ

225.07

-1.1%↓

ABT

92.85

+1.8%↑

MDT

82.92

-0.55%↓

115.57

+0.14%↑

VEEV

160.16

-0.42%↓

JNJ

225.07

-1.1%↓

ABT

92.85

+1.8%↑

MDT

82.92

-0.55%↓

115.57

+0.14%↑

VEEV

160.16

-0.42%↓

JNJ

225.07

-1.1%↓

ABT

92.85

+1.8%↑

MDT

82.92

-0.55%↓

115.57

+0.14%↑

VEEV

160.16

-0.42%↓

JNJ

225.07

-1.1%↓

ABT

92.85

+1.8%↑

MDT

82.92

-0.55%↓

115.57

+0.14%↑

VEEV

160.16

-0.42%↓

Kodu・Aktsiate loetelu・Vaxart Inc

Vaxart Inc

Suletud

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

Max

Põhinäitajad
By Trading Economics
Sissetulek	63M 55M
Müük	32M 104M
P/E Sektori keskmine	10.856 60.328
Aktsiakasum	0.24
Kasumimarginaal	52.807
Töötajad	65
EBITDA	63M 58M

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	12. mai 2026

Turustatistika
By TradingEconomics
Turukapital	-8.2M 184M
Eelmine avamishind	0
Eelmine sulgemishind	0

Tehniline skoor

By Trading Central

Kindlus

Bearish Evidence

0.4007 / 0.4252 Toetus ja vastupanu

Vaxart Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

27. apr 2026, 23:15 UTC

Uudisväärsed sündmused

U.K. Consumers Pay Less But Full Impact of Mideast War to Be Seen

27. apr 2026, 23:08 UTC

Tulu

Suurimad hinnamuutused turgudel

LendingClub Shares Gain on 1Q Profit, Revenue Beat

27. apr 2026, 23:58 UTC

Tulu

Samsung SDI 1Q Net Profit Beat FactSet-Compiled Consensus

27. apr 2026, 23:58 UTC

Tulu

Samsung SDI 1Q Net KRW56.10B Vs. Loss KRW216.00B >006400.SE

27. apr 2026, 23:56 UTC

Tulu

Samsung SDI 1Q Oper Loss KRW155.60B Vs. Loss KRW434.10B >006400.SE

27. apr 2026, 23:56 UTC

Tulu

Samsung SDI 1Q Rev KRW3.576T Vs. KRW3.177T >006400.SE

27. apr 2026, 23:48 UTC

Market Talk

Nikkei May Remain Rangebound Amid Uncertainty Over Iran Conflict -- Market Talk

27. apr 2026, 23:42 UTC

Market Talk

Australian Consumer Confidence Making a Slow Come Back -- Market Talk

27. apr 2026, 23:34 UTC

Market Talk

Uudisväärsed sündmused

Gold Edges Higher as Investors Assess Iran's Proposal to U.S. -- Market Talk

27. apr 2026, 23:30 UTC

Market Talk

Australia's NDIS Could Lose 'Social Licence' If Not Reined In -- Market Talk

27. apr 2026, 23:08 UTC

Market Talk

Polymetals's Revenue Outlook 'Extraordinary' for a Small-Cap Stock -- Market Talk

27. apr 2026, 23:02 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

27. apr 2026, 23:02 UTC

Market Talk

Warsh Will Probably Lean a Bit More Dovish Than Powell -- Market Talk

27. apr 2026, 22:42 UTC

Market Talk

BOJ Expected to Keep Rates On Hold; Guidance to Skew Hawkish -- Market Talk

27. apr 2026, 22:10 UTC

Tulu

Haier Smart Home: Results Also Weighed by Weak Demand in China-U.S. Markets >600690.SH

27. apr 2026, 22:09 UTC

Tulu

Haier Smart Home: Increase in Tariff Costs, Extreme Weather Conditions Hurt Results >600690.SH

27. apr 2026, 22:09 UTC

Tulu

Haier Smart Home 1Q Net CNY4.65B Vs. Net CNY5.49B >600690.SH

27. apr 2026, 22:09 UTC

Tulu

Haier Smart Home 1Q Rev CNY73.69B Vs. CNY79.12B >600690.SH

27. apr 2026, 21:56 UTC

Tulu

Tsingtao Brewery: Cost Controls Among Factors Supporting Results >0168.HK

27. apr 2026, 21:55 UTC

Tulu

Tsingtao Brewery 1Q Net CNY1.80B Vs. Net CNY1.71B >0168.HK

27. apr 2026, 21:55 UTC

Tulu

Tsingtao Brewery 1Q Rev CNY10.29B Vs. CNY10.45B >0168.HK

27. apr 2026, 21:44 UTC

Tulu

Tianqi Lithium: Higher Demand for Products From EV Sector Also Boosted Financial Performance >002466.SZ

27. apr 2026, 21:43 UTC

Tulu

Tianqi Lithium: Increase in Average Selling Prices of Major Lithium Products Supported Results >002466.SZ

27. apr 2026, 21:41 UTC

Tulu

Tianqi Lithium 1Q Rev CNY5.13B Vs. CNY2.58B >002466.SZ

27. apr 2026, 21:41 UTC

Tulu

Tianqi Lithium 1Q Net CNY1.88B Vs. Net CNY104.27M >002466.SZ

27. apr 2026, 20:50 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

27. apr 2026, 20:50 UTC

Market Talk

Uudisväärsed sündmused

Basic Materials Roundup: Market Talk

27. apr 2026, 20:50 UTC

Market Talk

Omandamised, ülevõtmised, äriostud

Financial Services Roundup: Market Talk

27. apr 2026, 20:50 UTC

Market Talk

Health Care Roundup: Market Talk

27. apr 2026, 20:39 UTC

Tulu

Nucor: Operating Segments Earnings Growth Driven by Trade Policies That Continue to Reduce Flood of Unfairly Traded Imports Into U.S. >NUE

Võrdlus sarnastega

Hinnamuutus

Vaxart Inc Prognoos

Hinnangu Konsensus

By TipRanks

0 ratings

Osta

Hoia

Müü

Põhineb 0 analüütiku instrumendi Vaxart Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

0.4007 / 0.4252Toetus ja vastupanu

Recent bearish events outweigh bullish events.

There is one bearish event.

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Vaxart Inc

Vaxart, Inc., a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII.4 norovirus strains; coronavirus vaccine, which is in Phase 2 clinical trial, for the treatment of SARS-CoV-2 infection; seasonal influenza vaccine, which is in Phase 2 clinical trial, to treat H1 influenza infection; and human papillomavirus therapeutic vaccine, which is in preclinical stage, that targets HPV-16 and HPV-18 for cervical cancers and precancerous cervical lesions. It has a license agreement with Altesa Biosciences, Inc. to develop and commercialize Vapendavir, a capsid-binding broad-spectrum antiviral. Vaxart, Inc. is headquartered in South San Francisco, California.